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T-ALL relapsing after allogeneic stem cell transplantation is unusual but classically associated with poor
outcome. Recently, encouraging results have been reported with Nelarabine in relapse or refractory cases. On
behalf of the Group of Research in Adult ALL (GRAALL), we conducted a retrospective analysis of patients
receiving Nelarabine following relapse after transplantation. Eleven patients received Nelarabine as salvage
therapy in this situation. Most of them were transplanted in ﬁrst Complete Remission (CR), and received
a myeloablative conditioning regimen in 7 cases. Relapse occurred with a median time of 199 days. Nelar-
abine was given at 1.5g/m2/day (Day 1, D3, D5) alone (N ¼ 5) or in association (N ¼ 6). The overall hema-
tological response rate was 81%. Neurologic toxicity represents the main adverse event (N ¼ 4), mainly
grade I-II. Event free survival and overall survival at 1 year were 70 and 90% respectively. Nelarabine is
a valuable option for salvage therapy in T-cell acute lymphoblastic leukemia relapsing after transplantation.
 2013 American Society for Blood and Marrow Transplantation.The prognosis of patients with T cell acute lymphoblastic presence of tumoral syndrome, karyotype, molecularTable 1
Transplantation Characteristics
Characteristics (N ¼ 11)
Disease status at transplantation
CR1 10
CR2 1
Median delay between diagnostic and
transplantation, days (range)
141 (89-1592)
Donor type
Matched-related 4
Unrelated (matched) 7 (3)
Source of stem cells (BM/PBSC/UCB) 4/6/1
Myeloablative (TBI)/reduced-intensity conditioning 7 (6)/4
GVHD prophylaxis
CsA-MTX 8
CsA-MMF 2leukemia or lymphoma (T-ALL/LL) has been reassessed,
based on monitoring of minimal residual disease levels and
new insights in pathogenesis (NOTCH1 pathway mutations)
[1,2]. To date, allogeneic hematopoietic stem cell trans-
plantation (HSCT) in ﬁrst complete remission remains the
standard option in patients with a high risk of relapse [3].
Relapse after transplantation is a very difﬁcult challenge and
is mostly associated with poor outcome.
Nelarabine is a prodrug of Ara-G, for which selective
cytotoxicity against T cell lymphoblast has been shown [4].
Nelarabine has been associated with a high response rate in
relapsing T-ALL/LL [5]. Little is available in the literature on
relapse of T-ALL after HSCT.We thus analyzed retrospectively
all patients with T-ALL who relapsed posttransplantation in
France from 2007 to 2010.
We conducted a retrospective study on behalf of the
Group of Research in Adult Acute Lymphoblastic Leukemia
(GRAALL). Centers from the GRAALL were asked about
patients having received nelarabine as salvage therapy
because of relapse after transplantation. We recorded data
concerning characteristics of the disease (leukocyte count,edgments on page 1125.
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2013 American Society for Blood and
13.04.010biology) at diagnosis and at relapse. Transplantation proce-
dure (conditioning regimen, graft-versus-host disease
[GVHD] prophylaxis) and complications (GVHD, in partic-
ular) were also investigated. Relapse was deﬁned as the
presence of more than 5% lymphoblasts as shown by bone
marrowaspiration, more than 20% in the peripheral blood, orCsA alone 1
Acute GVHD
Yes/no 8/3
Grades I-II/III-IV 8/0
Chronic GVHD
Yes/no 2/9
Extensive 1
CR indicates complete remission; BM, bone marrow; PBSC, peripheral blood
stem cell; UCB, umbilical cord blood; TBI, total body irradiation; CsA,
cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil.
Table 2
Relapse Characteristics
Characteristics No. of Incidences
Median time between transplantation
and relapse, days (range)
199 (119-2099)
Disease characteristics
Median WBC count, g/L 8, 6
Tumoral form 6/11
CNS involvement 2/11
Extramedullary presentation 7/11
WBC indicates white blood cell count; CNS, central nervous system.
Table 4
Neurological Toxicities
Patient No. Nervous System Disorder (NCI-CTCAE v2) Grade
3 Dysautonomia 1
4 Paresthesia 1
5 Peripheral sensory neuropathy 2
8 Ataxia/peripheral sensory neuropathy 2/3
E. Forcade et al. / Biol Blood Marrow Transplant 19 (2013) 1124e1135 1125any evidence of clinical nodal or extranodal involvement (eg,
central nervous system). Treatments associated with nelar-
abine (eg, association of chemotherapy, donor lymphocytes
infusion) were also recorded. Efﬁcacy of the treatment was
established according to blood cell count, marrow aspiration,
and computed tomography scan if necessary, in case of
tumoral presentation. Any available supplementary infor-
mation concerning level of remission (eg, molecular remis-
sion) was recorded. Safety was established according to
National Cancer InstituteeCommon Toxicity Criteria for
Adverse Events version 2 (NCI-CTCAE v2). Survival was
analyzed from the time of stem cell transplantation.
Between 2004 and 2010, 11 patients from 5 centers
received nelarabine as salvage therapy of 14 patients with
T-ALL/LL relapsing after HSCT. At time of diagnosis, median
age was 23 years (range, 14 to 62). None of the patients was
diagnosed with hyperleucocytosis (median white blood cell
count, 29 g/L). A tumoral formwas present in 9 patients, and
cytogenetic value was normal for almost half of the pop-
ulation. Most patients underwent HSCT in ﬁrst complete
response (median time between diagnosis and HSCT, 141
days), with a myeloablative conditioning regimen and from
unrelated donors (details of the transplantation procedure
are listed in Table 1).
GVHD prophylaxis consisted of cyclosporine-based
regimen for all patients, either associated with metho-
trexate, mycophenolate mofetil, or alone. Three patients
received antithymocyte globulin during the conditioning.
Relapse occurred with a median onset of 199 days
posttransplantation (range, 119 to 2099) with various char-
acteristics (Table 2). Six patients were still under immuno-
suppressive agents, because of slow tapering off or context of
GVHD, which was stopped quickly. One patient presented
with relapse in the context of chronic GVHD. This lastTable 3
Nelarabine-Based Salvage Therapy
Characteristic No. of
Incidences
Median delay between transplantation
and nelarabine, days (range)
244 (133-2126)
Induction chemotherapy
Nelarabine alone (number of patients) 5
Nelarabine in association (number
of patients)
6
HyperC 2
Non-hyperC 4
Median number of nelarabine cycles (number
of patients)
4
Number of patients receiving consolidation or
maintenance therapy
5
Secondary stem cell transplantation 0
HyperC indicates Cyclophosphamide 300mg/m2 twice a day, Day 1 to Day 3.situation raises the question of graft-versus-leukemia effect,
which is debated in ALL.
Patients were treated at the time of relapse with nelar-
abine, either alone (1.5 g/m2/day on days 1, 3, and 5, every 28
days) (n ¼ 5) or in association with other treatments (n ¼ 6).
Modalities of nelarabine-based treatment are listed in
Table 3. Among the 11 patients treated with nelarabine-
based salvage therapy, 81% achieved hematological
complete response with a median delay of 48 days. Two
patients in complete remission received donor lymphocytes
infusion (1 complete molecular response). Only 1 patient
presented acute GVHD after the nelarabine-based ﬁrst cycle
and required immunosuppressive treatment.
The main toxicity was neurological and involved 4
patients, with 2 patients experiencing grade II or more
adverse events (Table 4). Two questions remain unresolved
concerning the higher incidence of neurological toxicity. One
is the role of total body irradiationebased conditioning
before nelarabine treatment. The second is that 2 patients
had central nervous system involvement at the time of
relapse, requiring intrathecal injection of chemotherapy,
which could have contributed to the neurological toxicity.
At 1 year, disease-free and overall survival rates were 70%
and 90%, respectively. These results of survival are encour-
aging compared with those found concerning salvage treat-
mentwithnelarabineofﬁrstor secondary relapse,with28%of
overall survival at 1 year. The positive outcome of our study
seems to be higher than the Gökbuget study [5], but our study
concerns a small cohort within a particular setting.
One single patient presented with acute GVHD after
nelarabine-based salvage, which is not indicative of a causa-
tive link. Few data are available concerning interaction
between immunological posttransplantation status and
nelarabine. Literature suggests its preferential activity on
lymphoblasts than on mature lymphocytes [4].
In patients with T-ALL/LL relapsing after allogeneic HSCT,
nelarabine-based salvage therapy showed minor toxicity
and good efﬁcacy with a very high response rate (81%), with
some patients experiencing prolonged remission. Nelarabine
is thus a valuable option for patients with T-ALL experiencing
relapse after HSCTand should be considered formaintenance
therapy post-HSCT in high-risk patients, possibly driven by
minimum residual disease detection.ACKNOWLEDGMENTS
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We sought to determine if autologous umbilical cord blood (UCB) infusion followed by 1 year of supple-
mentation with vitamin D and docosahexaenoic acid (DHA) can preserve C-peptide in children with type 1
diabetes. We conducted an open-label, 2:1 randomized study in which 15 type 1 diabetes subjects with
stimulated C-peptide > .2 pmol/mL received either (1) autologous UCB infusion, 1 year of daily oral vitamin D
(2000 IU), and DHA (38 mg/kg) and intensive diabetes management or (2) intensive diabetes management
alone. Primary analyses were performed 1 year after UCB infusion. Treated (N ¼ 10) and control (N ¼ 5)
subjects had median ages of 7.2 and 6.6 years, respectively. No severe adverse events were observed.
Although the absolute rate of C-peptide decline was slower in treated versus control subjects, intergroup
comparisons failed to reach signiﬁcance (P ¼ .29). Area under the curve C-peptide declined and insulin use
increased in both groups (P < .01). Vitamin D levels remained stable in treated subjects but declined in control
subjects (P ¼ .01). DHA levels rose in treated subjects versus control subjects (P ¼ .003). CD4/CD8 ratio
remained stable in treated subjects but declined in control subjects (P ¼ .03). No changes were seen in
regulatory T cell frequency, total CD4 counts, or autoantibody titers. Autologous UCB infusion followed by
daily supplementation with vitamin D and DHAwas safe but failed to preserve C-peptide. Lack of signiﬁcance
may reﬂect small sample size. Future efforts will require expansion of speciﬁc immunoregulatory cell subsets,
optimization of combined immunoregulatory and anti-inﬂammatory agents, and larger study cohorts.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION development of low-risk (ie, safe) therapies for young chil-
We previously investigated the potential for a single
autologous umbilical cord blood (UCB) infusion to augment
the natural history of type 1 diabetes in very young children
[1-4]. Although our initial effort was not powered to
demonstrate efﬁcacy, the apparent safety of autologous UCB
infusion as well as the observed postinfusion increase in
peripheral blood regulatory T cell (Treg) frequency provided
impetus for additional studies. Given our group’s emphasis
on the potential for combination therapies to provide
synergy in attenuating autoimmunity and facilitating thedren with type 1 diabetes, we hypothesized that autologous
UCB therapy could be successfully augmented by the addi-
tion of two agents with well-characterized immunomodu-
latory properties and potential links to type 1 diabetes
pathophysiology, namely, vitamin D and docosahexaenoic
acid (DHA) [5,6]. As such, we sought to perform a follow-up
pilot study using this combination approach to document
safety and feasibility and to generate data to guide future
fully powered studies using autologous cell therapies.
METHODS
Participants
Children with type 1 diabetes older than 1 year of age and for whom
autologous UCB was stored were recruited for participation (NCT00873925;
FDA IND BB-11918).
Procedures
Potential subjects underwent a baseline 2-hour mixed meal tolerance
test to determine eligibility [1]. Subjects with peak C-peptide > .2 pmol/L
were randomized 2:1 (treatment-to-control) in an open-label manner. All
